Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Net Margin (2016 - 2025)

Cytokinetics (CYTK) has disclosed Net Margin for 16 consecutive years, with 269.98% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin changed N/A to 269.98% in Q4 2025 year-over-year; TTM through Dec 2025 was 248.22%, a N/A change, with the full-year FY2025 number at 747.21%, down 226958.0% from a year prior.
  • Net Margin was 269.98% for Q4 2025 at Cytokinetics, up from 9856.3% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 1122.4% in Q2 2024 to a low of 34233.07% in Q3 2023.
  • A 5-year average of 8233.46% and a median of 4582.31% in 2022 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: tumbled -2965076bps in 2023, then skyrocketed 1601213bps in 2024.
  • Cytokinetics' Net Margin stood at 64.69% in 2021, then tumbled by -10492bps to 6851.66% in 2022, then fell by -17bps to 8049.16% in 2023, then crashed by -302bps to 32338.88% in 2024, then surged by 99bps to 269.98% in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Net Margin are 269.98% (Q4 2025), 9856.3% (Q1 2025), and 32338.88% (Q3 2024).